# Cognizin (Citicoline)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/cognizin
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-29
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Citicoline, Cytidine 5'-diphosphocholine, CDP-choline, Cytidine diphosphate choline, Free-base citicoline, Citicolina, CDP-Cholin

## Overview

Cognizin is a patented, stabilized form of citicoline (cytidine 5'-diphosphocholine), a naturally occurring nucleotide that serves as a precursor to phosphatidylcholine in neuronal cell membranes. It supports [cognitive function](/ingredients/condition/cognitive) primarily by donating choline for acetylcholine synthesis and cytidine for uridine production, both critical for synaptic membrane integrity and neurotransmitter signaling.

## Health Benefits

• Limited clinical evidence available - research dossier contains no specific human trial outcomes or effect sizes
• Theoretical support for cognitive function through phosphatidylcholine synthesis and neurotransmitter production
• Potential [neuroprotective effect](/ingredients/condition/cognitive)s suggested but not clinically documented in provided research
• May support neuronal membrane integrity through phospholipid precursor activity
• Possible frontal cortex [energy production](/ingredients/condition/energy) enhancement based on mechanistic studies only

## Mechanism of Action

Citicoline is hydrolyzed in the gut into cytidine and choline, which cross the blood-brain barrier independently and reunite intracellularly to regenerate citicoline via the Kennedy pathway, ultimately producing phosphatidylcholine—a structural phospholipid essential for neuronal membrane repair and fluidity. The choline moiety also serves as a direct precursor for [acetylcholine](/ingredients/condition/cognitive) synthesis via choline acetyltransferase, enhancing cholinergic neurotransmission. Additionally, cytidine is converted to uridine, which upregulates dendritic spine density and supports [dopamine](/ingredients/condition/mood) receptor expression, potentially modulating dopaminergic tone in prefrontal circuits.

## Clinical Summary

Several randomized controlled trials have investigated citicoline at doses of 250–2000 mg/day in populations ranging from healthy adults to patients with age-associated memory impairment and mild vascular [cognitive](/ingredients/condition/cognitive) impairment, with sample sizes typically between 30 and 300 participants. A double-blind trial by Spiers et al. (1996) reported significant improvements in verbal memory in older adults receiving 1000 mg/day over 3 months compared to placebo. Cognizin-specific branded studies, including a small RCT (n=60) published in the Journal of Attention Disorders (McGlade et al., 2012), found improvements in attentional performance and psychomotor speed in adolescents at 250–500 mg/day, though the study was industry-funded. Overall, evidence is promising but limited by small sample sizes, short durations, and heterogeneous populations, and Cognizin-specific large-scale independent trials remain sparse.

## Nutritional Profile

Citicoline (CDP-choline) is a nucleotide compound, not a conventional macronutrient or micronutrient source. It contributes negligible caloric value (~0 kcal per typical dose). Primary bioactive components per standard 250–500 mg dose: Choline fraction ~18–22% by molecular weight (~45–110 mg choline equivalents per 250–500 mg dose), and Cytidine fraction ~26–30% by molecular weight (~65–150 mg cytidine per 250–500 mg dose). Cytidine is converted to uridine in peripheral tissues, a pyrimidine nucleoside involved in RNA synthesis and phospholipid [metabolism](/ingredients/condition/weight-management). Choline component contributes to the body's choline pool, supporting [acetylcholine](/ingredients/condition/cognitive) synthesis and serving as a methyl donor via conversion to betaine. No meaningful protein, fat, dietary fiber, or conventional micronutrient (vitamins/minerals) content. Bioavailability is notably high: oral bioavailability reported at approximately 90–100% in animal models, with human pharmacokinetic studies showing rapid hydrolysis in intestinal wall and liver into choline and cytidine before reassembly as citicoline in neural tissues. Peak plasma choline levels observed within 1–2 hours post-ingestion. Crosses the blood-brain barrier indirectly via constituent components. No significant vitamin or mineral contribution at supplemental doses.

## Dosage & Preparation

No clinically studied dosage ranges for Cognizin or citicoline forms are specified in the available research. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Citicoline is generally well tolerated; reported side effects at doses up to 2000 mg/day include mild gastrointestinal upset, headache, [insomnia](/ingredients/condition/sleep), and transient changes in [blood pressure](/ingredients/condition/heart-health), occurring at low incidence rates in clinical trials. It may potentiate the effects of levodopa, and caution is advised when combining it with cholinergic drugs such as [acetylcholine](/ingredients/condition/cognitive)sterase inhibitors (e.g., donepezil), as additive cholinergic activity could increase side effect risk. No established drug-drug interaction data exist for anticoagulants or CNS stimulants, though theoretically enhanced [dopamine](/ingredients/condition/mood)rgic signaling warrants monitoring alongside stimulant medications. Citicoline has not been adequately studied in pregnant or breastfeeding women, and its use is not recommended during pregnancy without medical supervision.

## Scientific Research

The research dossier notably lacks specific human RCTs, meta-analyses, or PubMed citations for Cognizin/citicoline trials. No clinical trial data including study designs, sample sizes, or measured outcomes are provided in the available research.

## Historical & Cultural Context

As a synthetic molecule that also occurs endogenously, citicoline/Cognizin has no traditional medicine history or cultural use documented. The compound represents modern nutritional science rather than traditional herbalism.

## Synergistic Combinations

Phosphatidylserine, Alpha-GPC, DHA omega-3, B-complex vitamins, Ginkgo biloba

## Frequently Asked Questions

### What is the recommended dosage of Cognizin citicoline for cognitive support?

Clinical trials supporting cognitive benefits have used doses ranging from 250 mg to 2000 mg of citicoline per day, with the most commonly studied effective range being 500–1000 mg daily. The Cognizin-branded adolescent study used 250–500 mg/day and observed attentional improvements within 28 days. Most supplement formulations provide 250–500 mg per serving, and splitting the dose morning and afternoon may minimize potential sleep disturbance.

### How long does it take for Cognizin citicoline to work?

Clinical trials reporting cognitive improvements have generally run for 4 to 12 weeks, suggesting that consistent daily use over at least one month is likely necessary to observe measurable benefits. Some neuroimaging research indicates that frontal lobe bioenergetics measured by phosphorus MRS can show changes within 6 weeks of supplementation at 500 mg/day. Acute single-dose effects on attention have been reported anecdotally but are not well established in controlled research.

### Is Cognizin citicoline the same as regular citicoline?

Cognizin is a patented, proprietary form of citicoline manufactured by Kyowa Hakko Bio Co., produced via a fermentation process intended to ensure high purity and bioavailability. Chemically, it is the same molecule—cytidine 5'-diphosphocholine—as generic citicoline, and its mechanism of action is identical. The primary distinction lies in quality control, manufacturing standardization, and the fact that most branded clinical trials have used Cognizin specifically, meaning the evidence base is more directly tied to this form.

### Can Cognizin citicoline be taken with caffeine or other nootropics?

Citicoline is frequently combined with caffeine in nootropic stacks, and a small study (Dodd et al., 2015) suggested that the combination of 250 mg citicoline with 150 mg caffeine produced greater improvements in attention and psychomotor speed than caffeine alone without increasing side effects. It is also commonly paired with racetams like piracetam, as citicoline can offset the choline demand these compounds create in the brain. No clinically significant adverse interactions have been documented with caffeine, but combining citicoline with prescription stimulants such as amphetamines should be done under medical guidance due to overlapping dopaminergic activity.

### Does citicoline increase acetylcholine levels in the brain?

Yes, citicoline donates free choline following intestinal hydrolysis, and this choline is transported across the blood-brain barrier where it serves as the rate-limiting substrate for acetylcholine biosynthesis via the enzyme choline acetyltransferase. Animal studies have demonstrated measurable increases in brain acetylcholine concentrations following citicoline administration, and this cholinergic enhancement is considered one of its primary mechanisms underlying memory and attention benefits. In humans, direct measurement of acetylcholine is not feasible without invasive methods, but indirect markers such as cognitive task performance align with the cholinergic hypothesis.

### What does clinical research show about Cognizin citicoline's effectiveness?

Current research on Cognizin citicoline is primarily theoretical, supported by its mechanism as a phosphatidylcholine precursor and acetylcholine precursor rather than robust human clinical trial data. While the ingredient has theoretical neuroprotective potential through support of neuronal membrane integrity, specific human trial outcomes and measurable effect sizes are limited in available research. Most evidence supports its role in supporting cognitive function pathways rather than demonstrating clinically significant improvements in independent studies. Additional rigorous human trials would be needed to establish definitive efficacy claims.

### Is Cognizin citicoline safe to take during pregnancy or while breastfeeding?

Safety data for Cognizin citicoline during pregnancy and breastfeeding is not well-established in clinical literature, making it prudent to avoid supplementation during these periods without explicit medical guidance. While citicoline is a naturally occurring compound involved in normal brain development, branded Cognizin supplementation has not been specifically studied in pregnant or nursing populations. Women who are pregnant, planning to become pregnant, or breastfeeding should consult with a healthcare provider before using this ingredient. Standard precautionary practice recommends avoiding supplementation when safety evidence is insufficient.

### Does Cognizin citicoline interact with prescription medications like blood thinners or psychiatric drugs?

Specific drug interaction data for Cognizin citicoline with blood thinners, antidepressants, antipsychotics, or other common medications is limited in available clinical literature. As a naturally occurring compound and acetylcholine precursor, theoretical interactions are possible with medications affecting cholinergic systems or blood pressure, though documented cases are rare. Anyone taking prescription medications—particularly those affecting neurotransmitters, blood clotting, or blood pressure—should consult a healthcare provider before adding Cognizin supplementation. Professional guidance ensures safe concurrent use based on individual medical history.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*